Skip to main content

Table 1 General characteristics for the enrolled patients in this study

From: Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment

Variables

Patients (n = 50)

Age; years

43.8 ± 9.75

Sex; male (%)

34 (68%)

Past history of schistosomiasis; yes (%)

6 (12%)

Fasting Blood Sugar (FBS); (mg/dl)

102.1 ± 23.5

Creatinine; (mg/dl)

0.91 ± 0.3

White blood cells (WBC); count × 103

6.41 ± 1.97

Hemoglobin; (gm/dl)

13.5 ± 1.67

Platelet count; × 103

197.8 ± 44.75

Aspartate transaminase (AST); (IU/l)

54.8 ± 23.5

Alanine transaminase (ALT); (IU/l)

53.7 ± 34

Albumin; (gm/dl)

4.2 ± 0.4

Prothrombin Concentration (%)

89.4 ± 8

Total bilirubin; (mg/dl)

0.8 ± 0.35

α-fetoprotein (AFP); (ng/ml)

10.7 ± 25.35

Viral titer

13,430,455 ± 10,850,375

Child-Pugh score

 Child A

50 (100%)

Liver sonography

 Cirrhosis

36 (72%)

 Hepatomegaly

10 (20%)

 Normal

4 (8%)

Virological response to DAA

 Responders

47 (94%)

  1. Values expressed as absolute numbers, percentages or mean ± SD